Document:

EX-10.2

 Exhibit 10.2 

SCICLONE PHARMACEUTICALS, INC. 

EMPLOYEE RETENTION AGREEMENT 

This EMPLOYEE RETENTION AGREEMENT (the
“Agreement”) is effective as of [●], by and between [EMPLOYEE NAME] (“Employee”) and SciClone Pharmaceuticals, Inc., a Delaware corporation (the
“Company”). For all purposes under this Agreement, the term “Company” shall include any successor to the Company’s business and/or assets, or any subsidiary of the Company or its successor. 

RECITALS 
 A. Employee
presently serves as [●] of the Company and performs significant strategic and management responsibilities necessary to the continued conduct of the Company’s business and operations. 

B. The Board of Directors of the Company (the “Board”) through
its Compensation Committee has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Employee. 

C. The Board believes that it is imperative to provide Employee with certain severance benefits upon Employee’s termination of employment
under circumstances described in this Agreement that will provide Employee with enhanced financial security and provide sufficient incentive and encouragement to Employee to remain with the Company. 

AGREEMENT 
 Employee and
the Company agree as set forth below: 
 1. Terms of Employment. The Company and Employee agree that Employee’s employment is
“at will” and that their employment relationship may be terminated by either party at any time, with or without cause, and, if applicable, in accordance with Section 2 or Section 4 below. If Employee’s employment with the
Company terminates for any reason, Employee shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided by this Agreement. During his or her employment with the Company, Employee agrees to devote his or
her full business time, energy and skill to his or her duties with the Company. These duties shall include, but not be limited to, any duties consistent with Employee’s position that may be assigned to Employee from time to time by the Company
or the Board. 
 2. Termination Other than During Change in Control Period. 

(a) Termination without Cause. Subject to the limitations set forth in Sections 5 and 6, if Employee’s employment with the
Company is terminated without Cause other than during a Change in Control Period, then Employee shall be entitled to receive, in addition to the compensation and benefits earned by Employee through the date of his or her termination
(“Accrued Compensation”), severance benefits as follows: 

 (i) Base Salary Continuation Benefit. Continuation of Employee’s base salary in
effect on Employee’s termination date for a period of [●] ([●]) months following such termination date, with such base salary to be paid in installments on the Company’s regular payroll dates beginning on the earlier of
(A) the first regular payroll date following the date on which the Release (as defined in Section 5) becomes effective and (B) the seventy-fourth (74th) day following Employee’s termination date; provided that if such
seventy-four (74) day period spans two calendar years, the installment payments shall begin in the second such calendar year. The initial payment of continued base salary will include a catch-up payment consisting of the installments that
otherwise would have been paid on the regular payroll dates occurring between Employee’s termination date and such initial payment date. 

(ii) Separation Bonus Benefit. A separation bonus equal to the gross amount of [●] percent ([●] %) of the average of
Employee’s annual performance bonus earned for the two (2) most recent fiscal years for which bonuses have been earned prior to the termination date shall be paid in a lump sum on the date on which the initial installment of base salary
continuation described in clause (i) above is paid. 
 (iii) Share-Based Compensation Awards. The treatment of share-based
compensation awards upon Employee’s termination of Employment covered by this Section (a) shall be determined in accordance with the terms of the plans or agreements providing for such awards. 

(iv) Healthcare Benefit. The Company shall, if permitted under the Company’s existing health insurance plans, continue
Employee’s existing group health insurance coverage. If not so permitted, the Company shall reimburse Employee for any COBRA premiums paid by Employee for continued group health insurance coverage. Such health insurance coverage or
reimbursement of COBRA premiums shall continue until the earlier of (A) twelve (12) months after the date of Employee’s termination of employment or (B) the date on which Employee commences New Employment (in either case, the
“COBRA Period”). Notwithstanding the foregoing, if the Company determines, in its sole discretion, that its reimbursement of the COBRA premiums would result in a violation of the nondiscrimination rules of
Section 105(h)(2) of the Internal Revenue Code of 1986, as amended (the “Code”) or any statute or regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended
by the 2010 Health Care and Education Reconciliation Act), then in lieu of reimbursing the COBRA premiums, the Company shall instead pay to Employee on the first day of each month of the COBRA Period, a fully taxable cash payment equal to the COBRA
premiums for that month, subject to applicable tax withholdings (such amount, the “Special Severance Payment”), for the remainder of the COBRA Period. Employee may, but is not obligated to, use such Special Severance Payment
toward the cost of COBRA premiums. 
 (b) Voluntary Resignation; Termination For Cause. If Employee’s employment terminates by
reason of Employee’s voluntary resignation (but not as a result of termination by the Company without Cause) or as a result of Employee’s termination by the Company for Cause, then Employee shall be entitled only to Employee’s Accrued
Compensation and shall not be entitled to receive any severance benefits under this Agreement. 

  
 2 

 (c) Disability; Death. If the Company terminates Employee’s employment as a result of
Employee’s Disability or death, then Employee shall be entitled only to Employee’s Accrued Compensation and shall not be entitled to receive any severance benefits under this Agreement. 

3. Treatment of Equity Awards Upon a Change in Control. 

(a) Effect of Non-Assumption. Except as provided by Section 3(b) below, notwithstanding any provision to the contrary contained in
any plan or agreement evidencing a share-based compensation award with respect to Company common stock held by Employee (an “Equity Award”), in the event of a Change in Control in which the surviving, continuing, successor,
or purchasing corporation or other business entity or parent thereof, as the case may be (the “Acquiror”), does not assume or continue the Company’s rights and obligations under a then-outstanding Equity Award or
substitute for such Equity Award a substantially equivalent share-based compensation award with respect to the Acquiror’s capital stock, then the vesting, exercisability and settlement (as applicable) of such Equity Award shall be accelerated
in full effective immediately prior to, but conditioned upon, the consummation of the Change in Control. For purposes of this Section, an Equity Award shall be deemed assumed if, following the Change in Control, the Equity Award confers the right of
Employee to receive, subject to the terms and conditions of the applicable Company equity incentive plan and award agreement evidencing such Equity Award, for each share of Company common stock subject to the Equity Award immediately prior to the
Change in Control, the consideration (whether shares, cash, other securities or property or a combination thereof) to which a holder of a share of Company common stock on the effective date of the Change in Control was entitled (and if holders were
offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Company common stock); provided, however, that if such consideration is not solely common stock of the Acquiror, the
Compensation Committee of the Board may, with the consent of the Acquiror, provide for the consideration to be received upon the exercise or settlement of the Equity Award, for each share subject to the Equity Award, to consist solely of common
stock of the Acquiror equal in fair market value to the per share consideration received by holders of Company common stock pursuant to the Change in Control. 

(b) Other Share-Based Compensation Awards. Notwithstanding Section 3(a) or anything else in this Agreement to the contrary, the
treatment of an Equity Award upon the consummation of a Change in Control, including but not limited to the acceleration thereof, shall be determined in accordance with the terms of the applicable Company equity incentive plan and award agreement
evidencing such Equity Award if their terms provide treatment that is more favorable to Employee than the treatment provided by this Agreement. 

4. Termination During Change in Control Period. 

(a) Involuntary Termination. Subject to the limitations set forth in Sections 5 and 6, if Employee’s employment with the
Company terminates as a result of Involuntary Termination during a Change in Control Period, then Employee shall be entitled to receive, in addition to Employee’s Accrued Compensation, severance benefits as follows: 

(i) Base Salary Benefit. An amount equal to [●] percent ([●] %) of Employee’s annual base salary as in effect at
the time of such termination (without giving effect 

  
 3 

 
to any reduction in base salary that would constitute Constructive Termination) shall be paid to Employee in a lump sum on the earlier of (A) the Company’s first regular payroll date
following the date on which the Release (as defined in Section 5) becomes effective and (B) the seventy-fourth (74th) day following Employee’s termination date; provided that if such seventy-four (74) day period spans two
calendar years, the payment shall be made in the second such calendar year; and provided further, however, that if the Change in Control does not constitute a “change in control event” as defined by Treasury Regulation
Section 1.409A-3(i)(5) or any successor thereto, then the severance amount required by this clause (i) shall be divided into installments and paid at the times and in the manner such installments would be paid in accordance with
Section 2(a)(i). 
 (ii) Separation Bonus Benefit. A separation bonus equal to the gross amount of [●] percent
([●] %) of the average of Employee’s annual performance bonus earned for the two (2) most recent fiscal years for which bonuses have been earned prior to the termination date shall be paid at the same time(s) and in the same
manner as the severance benefit described in clause (i) above is paid. 
 (iii) Share-Based Compensation Awards. All Options
and other share-based compensation awards (but excluding Options and other share-based compensation awards subject to performance-based vesting, whether or not also subject to service-based vesting) held by Employee shall become vested in full as of
Employee’s termination date, and such Options shall remain exercisable until the earlier of twelve (12) months following Employee’s termination date or the expiration of their term. 

(iv) Healthcare Benefit. The Company shall, if permitted under the Company’s existing health insurance plans, continue
Employee’s existing group health insurance coverage. If not so permitted, the Company shall reimburse Employee for any COBRA premiums paid by Employee for continued group health insurance coverage. Such health insurance coverage or
reimbursement of COBRA premiums shall continue until the earlier of (A) the date twelve (12) months after the date of Employee’s termination of employment or (B) the date on which Employee commences New Employment.
Notwithstanding the foregoing, if the Company determines, in its sole discretion, that its reimbursement of the COBRA premiums would result in a violation described in Section 2(a)(iv), the Company shall pay to Employee the Special Severance
Payment described in Section 2(a)(iv). 
 (b) Voluntary Resignation; Termination For Cause. If Employee’s employment
terminates during the Change in Control Period by reason of Employee’s voluntary resignation (but not as a result of an Involuntary Termination) or as a result of Employee’s termination by the Company for Cause, then Employee shall be
entitled only to Employee’s Accrued Compensation and shall not be entitled to receive any severance benefits under this Agreement. 

(c) Disability; Death. If the Company terminates Employee’s employment as a result of Employee’s Disability or death, then
Employee shall be entitled only to Employee’s Accrued Compensation and shall not be entitled to receive any severance benefits under this Agreement. 

  
 4 

 5. Release of Claims; Resignation. Employee’s entitlement to any severance pay or
benefits under this Agreement is conditioned upon Employee’s execution and delivery to the Company of (a) a general release of known and unknown claims substantially in the form attached hereto as Exhibit A which becomes effective
in accordance with its terms on or before the sixtieth (60th) day following Employee’s termination date and (b) resignation from all of Employee’s positions with the Company, including from the Board of Directors and any
committees thereof on which Employee serves, in a form satisfactory to the Company. 
 6. Certain Tax Matters. 

(a) Parachute Payments. In the event that any payment or benefit received or to be received by Employee pursuant to this Agreement or
otherwise (collectively, the “Payments”) would result in a “parachute payment” as described in Section 280G of the Code, then notwithstanding the other provisions of this Agreement the amount of
such Payments will not exceed the amount which produces the greatest after-tax benefit to Employee. For purposes of the foregoing, the greatest after-tax benefit will be determined within thirty (30) days of the occurrence of such payment to
Employee, in Employee’s sole and absolute discretion. If no such determination is made by Employee within thirty (30) days of the occurrence of such payment, the Company will promptly make such determination in a fair and equitable manner.

 (b) Section 409A. The Company and Employee intend that this Agreement (and all payments and other benefits provided under
this Agreement) be exempt from the requirements of Section 409A of the Code and the regulations and ruling issued thereunder (collectively “Section 409A”), to the maximum extent possible, whether pursuant to the
short-term deferral exception described in Treasury Regulation Section 1.409A-1(b)(4), the involuntary separation pay plan exception described in Treasury Regulation Section 1.409A-1(b)(9)(iii), or otherwise. To the extent
Section 409A is applicable to such payments, the Company and Employee intend that this Agreement (and such payments and benefits) comply with the deferral, payout and other limitations and restrictions imposed under Section 409A.
Notwithstanding any other provision of this Agreement to the contrary, this Agreement shall be interpreted, operated and administered in a manner consistent with such intentions. Without limiting the generality of the foregoing, and notwithstanding
any other provision of this Agreement to the contrary: 
 (i) No amount payable pursuant to this Agreement on account of Employee’s
termination of employment with the Company which constitutes a “deferral of compensation” within the meaning of Section 409A shall be paid unless and until Employee has incurred a “separation from service” within the meaning
of Section 409A. Furthermore, to the extent that Employee is a “specified employee” within the meaning of Section 409A (determined using the identification methodology selected by Company from time to time, or if none, the
default methodology) as of the date of Employee’s separation from service, no amount that constitutes a deferral of compensation which is payable on account of Employee’s separation from service shall paid to Employee before the date (the
“Delayed Payment Date”) which is first day of the seventh month after the date of Employee’s separation from service or, if earlier, the date of Employee’s death following such separation from service. All such
amounts that would, but for this Section, become payable prior to the Delayed Payment Date will be accumulated and paid in a lump sum on the Delayed Payment Date. Thereafter, any payments that remain outstanding as of the day immediately following
the Delayed Payment Date shall be paid without delay over the time period originally scheduled, in accordance with the terms of this Agreement. 

  
 5 

 (ii) The Company and Employee intend that any right of Employee to receive installment payments
hereunder shall, for all purposes of Section 409A, be treated as a right to a series of separate payments. 
 (iii) Neither the
Company nor Employee shall have the right to accelerate or defer any payment or benefit under this Agreement except to the extent specifically permitted or required by Section 409A. 

(iv) Whenever a payment under this Agreement specifies a payment period with reference to a number of days (e.g. “payment shall be made
within thirty (30) days following the date of termination”), the actual date of payment within the specified period shall be within the sole discretion of the Company. 

(v) With regard to any provision in this Agreement that provides for reimbursement of expenses or in-kind benefits, except for any expense,
reimbursement or in-kind benefit provided pursuant to this Agreement that does not constitute a “deferral of compensation,” within the meaning of Section 409A, (A) the right to reimbursement or in-kind benefits shall not be
subject to liquidation or exchange for another benefit, (B) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits
to be provided, in any other taxable year, provided that the foregoing clause (B) shall not be deemed to be violated with regard to expenses reimbursed under any arrangement covered by Section 105(b) of the Code solely because such
expenses are subject to a limit related to the period the arrangement is in effect, and (C) such payments shall be made on or before the last day of Employee’s taxable year following the taxable year in which the expense occurred. 

(vi) The Company intends that income provided to Employee pursuant to this Agreement will not be subject to taxation under Section 409A.
However, the Company does not guarantee any particular tax effect for income provided to Employee pursuant to this Agreement. In any event, except for the Company’s responsibility to withhold applicable income and employment taxes from
compensation paid or provided to Employee, the Company shall not be responsible for the payment of any applicable taxes on compensation paid or provided to Employee pursuant to this Agreement. 

(c) Tax Withholding. The Company may withhold from any amounts payable under this Agreement such taxes or other amounts as shall be
required to be withheld pursuant to applicable law or regulation. 
 7. Consulting Services. During the [●] ([●]) months
following any termination of Employee’s employment described in Section 2(a) or Section 4(a), Employee shall be retained by the Company as an independent contractor to provide consulting services to the Company at its request for up
to (but no more than) eight (8) hours per week. These services shall include any reasonable requests for information or assistance by the Company, including, but not limited to, the transition of Employee’s duties. Such services shall be
provided at mutually convenient 

  
 6 

 
times. For the actual provision of such services, the Company shall pay to Employee a consulting fee of $1,000 per eight hour day, pro-rated for the number of hours of service, plus reasonable
out-of-pocket expenses (for example, travel and lodging). 
 8. Definition of Terms. The following terms referred to in this
Agreement shall have the following meanings: 
 (a) “Cause” means any of the following: 

(i) Employee’s theft, dishonesty, misconduct or falsification of any records of the Company; 

(ii) Employee’s misappropriation or improper disclosure of confidential or proprietary information of the Company; 

(iii) any intentional action by Employee which has a material detrimental effect on the reputation or business of the Company; 

(iv) Employee’s failure or inability to perform any reasonable assigned duties after written notice from the Company of, and a
reasonable opportunity to cure, such failure or inability; 
 (v) any material breach by Employee of any employment agreement between
Employee and the Company, which breach is not cured pursuant to the terms of such agreement; or 
 (vi) Employee’s conviction of any
criminal act which impairs Employee’s ability to perform his or her duties for the Company. 
 (b) “Change in
Control” means any of the following: (i) a merger or other transaction in which the Company or substantially all of its assets is sold or merged and as a result of such transaction, the holders of the Company’s common
stock prior to such transaction do not own or control a majority of the outstanding shares of the successor corporation, (ii) the election of nominees constituting a majority of the Board which nominees were not approved by a majority of the
Board prior to such election, or (iii) the acquisition by a third party of twenty percent (20%) or more of the Company’s outstanding shares which acquisition was without the approval of a majority of the Board in office prior to such
acquisition. 
 (c) “Change in Control Period” means the period commencing upon the consummation of a Change in
Control and ending on the first anniversary of such Change in Control. 
 (d) “COBRA” means the Consolidated Omnibus
Budget Reconciliation Act of 1985, as amended. 
 (e) “Constructive Termination” means any one or more
of the following conditions: 

  
 7 

 (i) without Employee’s express written consent, the assignment to Employee, following a
Change in Control, of any title or duties, or any limitation of Employee’s responsibilities, that are substantially and adversely inconsistent with Employee’s title(s), duties, or responsibilities with the Company immediately prior to the
date of the Change in Control; 
 (ii) without Employee’s express written consent, the relocation of the principal place of
Employee’s employment, following Change in Control, to a location that is more than fifty (50) miles from Employee’s principal place of employment immediately prior to the date of the Change in Control, or the imposition of travel
requirements substantially more demanding of Employee than such travel requirements existing immediately prior to the date of the Change in Control; 

(iii) any failure by the Company, following a Change in Control, to pay, or any material reduction by the Company of,
(A) Employee’s base salary in effect immediately prior to the date of the Change in Control, or (B) Employee’s bonus compensation, if any, in effect immediately prior to the date of the Change in Control (subject to applicable
performance requirements with respect to the actual amount of bonus compensation earned by Employee), unless base salary and/or bonus reductions comparable in amount and duration are concurrently made for a majority of the other employees of the
Company who have substantially similar titles and responsibilities as Employee; and 
 (iv) any failure by the Company, following a Change
in Control, to (A) continue to provide Employee with the opportunity to participate, on terms no less favorable than those in effect for the benefit of any employee group which customarily includes a person holding the employment position or a
comparable position with the Company then held by Employee, in any benefit or compensation plans and programs, including, but not limited to, the Company’s life, disability, health, dental, medical, savings, profit sharing, stock purchase and
retirement plans, if any, in which Employee was participating immediately prior to the date of the Change in Control, or in substantially similar plans or programs, or (B) provide Employee with all other fringe benefits (or substantially
similar benefits), including, but not limited to, relocation benefits, provided to any employee group which customarily includes a person holding the employment position or a comparable position with the Company then held by Employee, which Employee
was receiving immediately prior to the date of the Change in Control. 
 However, the occurrence of the foregoing conditions shall not constitute a
Constructive Termination unless (A) Employee has given written notice of the occurrence of any such condition(s) to the Chairman of the Board within sixty (60) days following the date on which Employee knows, or with the exercise of
reasonable diligence would know, of the occurrence of any of such conditions, (B) the Company fails to cure the condition(s) constituting Constructive Termination within twenty (20) days after receipt of such written notice thereof, and
(C) Employee terminates employment with the Company within thirty (30) days following expiration of such cure period. 
 (f)
“Disability” means the inability of Employee, in the opinion of a qualified physician, to perform the essential functions of Employee’s position with the Company, with or without reasonable accommodation,
because of the sickness or injury of Employee. 

  
 8 

 (g) “Involuntary Termination” means the occurrence of
either of the following events during a Change in Control Period: 
 (i) termination by the Company of Employee’s employment without
Cause; or 
 (ii) Employee’s Constructive Termination. 

“Involuntary Termination” shall not include any termination of Employee’s employment that is (1) for Cause, (2) a result of
Employee’s death or Disability, or (3) a result of Employee’s voluntary resignation. 
 (h) “New
Employment” means any employment obtained by Employee after the termination of Employee’s employment with the Company. 

9. Nonsolicitation. During his or her employment with the Company, and for a period of one (1) year following the termination of
his or her employment for any reason, Employee shall not directly or indirectly recruit, solicit, or induce any person who on the date hereof is, or who subsequently becomes, an employee, sales representative or consultant of the Company, to
terminate his or her relationship with the Company. 
 10. Successors. 

(a) Company’s Successors. Any successor to the Company or to all or substantially all of the Company’s business and/or assets
shall be bound by this Agreement in the same manner and to the same extent as the Company. 
 (b) Employee’s Successors. All
rights of Employee hereunder shall inure to the benefit of, and be enforceable by, Employee’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. Employee shall have no right to
assign any of his obligations or duties under this Agreement to any other person or entity. 
 11. Notice. 

(a) General. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been
duly given when personally delivered or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid. In the case of Employee, mailed notices shall be addressed to Employee at the home address which he most recently
communicated to the Company in writing. In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary. 

(b) Notice of Termination. Any termination by the Company or Employee of their employment relationship shall be communicated by a
written notice of termination to the other party. 
 12. Miscellaneous Provisions. 

  
 9 

 (a) No Duty to Mitigate. Employee shall not be required to mitigate the amount of any
payment contemplated by this Agreement (whether by seeking New Employment or in any other manner), nor shall any such payment be reduced by any earnings that Employee may receive from any other source. 

(b) Waiver. No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is
agreed to in writing and signed by Employee and by an authorized officer of the Company (other than Employee). No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall
be considered a waiver of any other condition or provision or of the same condition or provision at another time. 
 (c) Choice of
Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of California. 

(d) Severability. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or
enforceability of any other provision hereof, which shall remain in full force and effect. 
 (e) Arbitration. In the event of any
dispute or claim relating to or arising out of Employee’s employment relationship with the Company, this Agreement, or the termination of Employee’s employment with the Company for any reason (including, but not limited to, any claims of
breach of contract, wrongful termination, fraud or age, race, sex, national origin, disability or other discrimination or harassment), Employee and the Company agree that all such disputes shall be fully, finally and exclusively resolved by binding
arbitration conducted by the American Arbitration Association in San Mateo County, California. Judgment upon any decision or award rendered by the arbitrator may be entered in any court having jurisdiction over the matter. Employee and the Company
knowingly and willingly waive their respective rights to have any such disputes or claims tried to a judge or jury. 
 (f) Prior
Agreements. Subject to Section 3(b) hereof, this Agreement supersedes all prior understandings and agreements, whether written or oral, regarding the subject matter of this Agreement. 

  
 10 

 IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company
by its duly authorized officer, as of the day and year first above written. 
  

			
	SCICLONE PHARMACEUTICALS, INC.
		
	By:	 	 
	
	EMPLOYEE
	
	  

	[EMPLOYEE NAME]

  
 11 

 Exhibit A 

RELEASE 
 In exchange for
the severance pay and benefits described in Employee Retention Agreement between SciClone Pharmaceuticals, Inc. (the “Company”) and me effective as of [●], I hereby release the Company, its parents and subsidiaries, and
their officers, directors, employees, attorneys, stockholders, successors, assigns and affiliates, of and from any and all claims, liabilities, and causes of action of every kind and nature, whether known or unknown, based upon or arising out of any
agreements, events, acts, omissions or conduct at any time prior to and including the execution date of this Release, including, but not limited to: all claims concerning my employment with the Company or the termination of that employment; all
claims pursuant to any federal, state or local law, statute, or cause of action, including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Americans with Disabilities Act of 1990; the federal Age Discrimination in
Employment Act of 1967, as amended (“ADEA”); the California Fair Employment and Housing Act, as amended; tort law; contract law; wrongful discharge; race, sex, age or other discrimination or harassment; fraud; defamation;
emotional distress; and breach of the implied covenant of good faith and fair dealing. 
 I am knowingly, willingly and voluntarily
releasing any claims I may have under the ADEA. I acknowledge that the consideration given for the release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been
advised by this writing, as required by the ADEA, that: (a) this Release does not apply to any rights or claims that may arise after I sign it; (b) I have the right to consult with an attorney prior to signing this Release; (c) I have
twenty-one (21) days to consider this Release (although I may choose to voluntarily sign this Release earlier); (d) I have seven (7) days after I sign this Release to revoke it; and (e) this Release shall not be effective until
the eighth day after it is signed by me. 
 In giving this release, which includes claims that may be unknown to me at present, I
acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the
time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby waive and relinquish all rights and benefits under that section and any law of any jurisdiction of
similar effect with respect to my release of any unknown claims I may have, and I affirm that it is my intention to release all known and unknown claims that I have or may have against the parties released above. 

  
 1 

 This Release contains the entire agreement between the Company and me regarding the subjects
above, and it cannot be modified except by a document signed by me and an authorized representative of the Company. 
  

							
		 		 	EMPLOYEE
				
	Date:	 		 		 	 
		 		 		 	[NAME]

  

									
		 		 	SCICLONE PHARMACEUTICALS, INC.
					
	Date:	 		 		 	By:	 	 
					
		 		 		 	Its:	 	 

  
 2Exhibit 10.1

 

Regeneron Pharmaceuticals, Inc. Cash Incentive Bonus Plan

 

The purposes of the Regeneron Pharmaceuticals, Inc. Cash Incentive Bonus Plan (this “Plan”) are to reinforce corporate, organizational and business development goals; to promote the achievement of year-to-year and long-term financial and other business objectives; to directly tie a portion of participants’ compensation to the performance of the Company (as defined below); and to reward the performance of individual officers and other employees in fulfilling their personal responsibilities for long-range achievements.

 

Section 1.                                                                               Definitions.  The following terms, as used herein, shall have the following meanings:

 

1.1                               “Annual Base Salary” shall mean: (i) with respect to any Executive Officer, the annual rate of base salary of such Executive Officer in effect as of the first day of any Performance Period (or, if an Executive Officer was not employed as of the first day of a Performance Period, the annual rate of base salary in effect as of such Executive Officer’s first day of employment); and (ii) with respect to any other Participant, unless otherwise determined by the Company, the annualized base salary paid to such Participant in respect of any Performance Period.

 

1.2                               “Award” shall mean non-equity incentive compensation award, granted pursuant to this Plan, which is contingent upon the attainment of Performance Goals with respect to a Performance Period.

 

1.3                               “Award Agreement” shall mean any written agreement, contract, notice or other instrument or document evidencing an Award.

 

1.4                               “Board” shall mean the Board of Directors of the Company.

 

1.5                               “CIC Plan” shall mean the Regeneron Pharmaceuticals, Inc. Change in Control Severance Plan, as amended from time to time.

 

1.6                               “Code” shall mean the Internal Revenue Code of 1986, as amended.

 

1.7                               “Committee” shall mean the Compensation Committee of the Board.  Notwithstanding anything herein to the contrary, with respect to any actions taken with respect to an Award granted to a Covered Employee that is intended to qualify as “performance-based compensation” as defined under Section 162(m) of the Code, the Committee shall consist solely of two or more persons, each of whom shall be an “outside director” within the meaning of Section 162(m) of the Code.

 

1.8                               “Company” shall mean Regeneron Pharmaceuticals, Inc.

 

1.9                               “Covered Employee” shall have the meaning set forth in Section 162(m)(3) of the Code.

 

1.10                        “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

 

 

1.11                        “Executive Officer” shall mean an “executive officer” of the Company within the meaning of the Exchange Act.

 

1.12                        “GAAP Measures” shall mean financial measures calculated in accordance with U.S. Generally Accepted Accounting Principles.

 

1.13                        “Non-GAAP Measures” shall mean financial measures not calculated in accordance with U.S. Generally Accepted Accounting Principles.

 

1.14                        “Participant” shall mean an officer or other employee of the Company or a subsidiary who is, pursuant to Section 4 of this Plan, selected to participate herein.

 

1.15                        “Performance Goal” shall mean the criteria and objectives, determined by the Committee, which must be met during the applicable Performance Period as a condition of the Participant’s receipt of payment with respect to an Award. Performance Goals may include one or more of the following: (1) total shareholder return; (2) return on equity; (3) return on invested capital; (4) cash flows; (5) earnings per share of Company stock; (6) net income (before or after taxes); (7) earnings before interest, taxes, depreciation and amortization (or earnings before interest, taxes and depreciation); (8) revenues (or specified revenues, such as licensing revenues); (9) return on assets; (10) market share; (11) cost reduction goals; (12) the initiation or completion of clinical trials; (13) the achievement of certain target levels of discovery and/or development of products, including, without limitation, the regulatory progress and approval of new products; (14) the achievement of certain target levels of sales of new products or licensing in or out of new products or product candidates; (15) the achievement of certain research and development objectives; (16) the formation of joint ventures, research or development collaborations, or the completion of other corporate transactions; (17) any combination of, or a specified increase in, any of the foregoing; and (18) such other criteria as the shareholders of the Company may approve. These performance goals may be set based on GAAP Measures and/or Non-GAAP Measures, and may be applied either individually, alternatively, or in any combination, either to the Company as a whole or to a defined business unit or function. In addition, such performance goals may be based upon the attainment of specified levels of Company performance under one or more measures described above on an absolute basis or relative to a pre-established target, to prior years’ results or to the performance of a designated comparison group, measured either annually, cumulatively over a period of years or for such other period as the Committee may determine. To the extent permitted under Section 162(m) of the Code (including, without limitation, compliance with any requirements for shareholder approval), the Committee may adjust, modify or amend the aforementioned business criteria. Without limiting the foregoing, the Committee may provide that any evaluation of performance shall include or exclude any of the following:  (1) asset write-downs; (2) litigation or claim judgments or settlements; (3) the effect of changes in tax laws, accounting principles, regulations, or other laws or regulations affecting reported results; (4) any reorganization and restructuring programs; (5) acquisitions or divestitures;  (6) unusual nonrecurring or unfrequently occurring items identified in the Company’s audited financial statements, including footnotes; (7) annual incentive payments or other bonuses; or (8) capital charges.  The Committee may also designate a Performance Goal, the attainment of which will govern the maximum amount a Participant may earn under this Plan for a Performance Period, and then utilize the Performance Goals (or such additional or different criteria as it many determine) to determine whether and to

 

2

 

what extent it will use “negative discretion” to reduce such maximum amount, consistent, where applicable, with the requirements of Section 162(m) of the Code.  To the extent an Award is intended to constitute qualified performance-based compensation for purposes of Section 162(m) of the Code, no amount shall be paid under any Award subject to such criteria, except only after the attainment of such performance measures has been certified by the Committee. To the extent an Award is not intended to constitute qualified performance-based compensation for purposes of Section 162(m) of the Code, additional or different performance criteria may be utilized and there shall be no requirement to comply with the other requirements imposed on qualified performance-based compensation under Section 162(m) of the Code.

 

1.16                        “Performance Period” shall mean, in respect of any Award, the Company’s fiscal year or such other period as the Committee may determine, subject to compliance with the requirements of Section 162(m) of the Code to the extent an Award is intended to constitute qualified performance-based compensation for purposes of such section.

 

Section 2.                                                                               Administration.

 

This Plan shall be administered by the Committee. The Committee shall have the authority in its sole discretion, subject to and not inconsistent with, the express provisions of this Plan, to administer this Plan and to exercise all the powers and authorities either specifically granted to it under this Plan or necessary or advisable in the administration of this Plan, including, without limitation, the authority to grant Awards; to determine the persons to whom and the time or times at which Awards shall be granted; to determine the duration of the Performance Period applicable to any Award; to determine the terms, conditions, restrictions and performance criteria, including Performance Goals, relating to any Award; to certify whether the Performance Goals have been attained; to determine whether, to what extent, and under what circumstances an Award may be settled, cancelled, forfeited, or surrendered; to make adjustments in the Performance Goals in recognition of unusual or nonrecurring events affecting the Company or the financial statements of the Company, or in response to changes in applicable laws, regulations, or accounting principles; to construe and interpret this Plan and any Award; to prescribe, amend and rescind rules and regulations relating to this Plan; to determine the terms and provisions of Award Agreements; and to make all other determinations deemed necessary or advisable for the administration of this Plan.

 

The Committee may appoint a chairperson and a secretary and may make such rules and regulations for the conduct of its business as it shall deem advisable, and shall keep minutes of its meetings. All determinations of the Committee shall be made by a majority of its members either present in person or participating by conference telephone at a meeting or by written consent. The Committee may delegate to one or more of its members or to one or more agents such administrative duties as it may deem advisable, and the Committee or any person to whom it has delegated duties as aforementioned may employ one or more persons to render advice with respect to any responsibility the Committee or such person may have under this Plan. All decisions, determinations and interpretations of the Committee shall be final and binding on all persons, including the Company, each Participant (or any person claiming any rights under this Plan from or through any Participant) and any shareholder.  No member of the Board or the Committee shall be liable for any action taken or determination made in good faith with respect to this Plan or any Award granted hereunder.  Notwithstanding anything in this Plan to the

 

3

 

contrary, to the extent consistent with Section 162(m) of the Code, the Committee may delegate the responsibility for administering this Plan to a subcommittee or an officer of the Company, subject to such limitations as the Committee deems appropriate. All references in this Plan to the “Committee” shall be, as applicable, to the Committee or any other committee or officer to whom the Committee has delegated authority to administer this Plan.

 

Section 3.                                                                               Eligibility.  Awards may be granted to officers and other employees of the Company and its subsidiaries in the sole discretion of the Committee.

 

Section 4.                                                                               Terms of Awards.

 

4.1                               Awards granted pursuant to this Plan may be (but are not required to be) evidenced by an Award Agreement in such form as the Committee shall from time to time approve.

 

4.2                               The Committee shall specify with respect to a Performance Period the Performance Goals applicable to each Award and minimum, target and maximum levels applicable to each Performance Goal. Awards for any Performance Period may be expressed as a dollar amount or as a percentage of the Participant’s Annual Base Salary. Unless otherwise provided by the Committee in connection with specified terminations of employment of Participants (which provisions shall be made in accordance with the provisions of Section 162(m) of the Code in the case of Covered Employees) or as otherwise provided in an employment or similar agreement between the Company and a Participant, payment in respect of Awards shall be made only if and to the extent the Performance Goals with respect to such Performance Period have been attained. Performance Goals applicable to a Performance Period (and any exclusions) shall be established by the Committee no later than the earlier of 90 days after commencement of the Performance Period or the expiration of 25% of the Performance Period, provided that the achievement of the selected Performance Goals for the Performance Period shall in any case be substantially uncertain at the time of establishment.

 

4.3                               To the extent the Performance Period under an Award exceeds one year, any Participant may be subject to multiple Awards at any time (where, for example, Awards with three-year Performance Periods are granted in consecutive years).  In any event, the maximum payout that an individual Participant may receive with respect to Awards granted in any fiscal year shall not exceed $10,000,000.

 

4.4                               Unless otherwise determined by the Committee, all payments with respect of Awards granted under this Plan shall be made, in cash, within a reasonable period (but in any event within 21⁄2 months) after the end of the Performance Period. In the case of Participants who are Covered Employees, such payments shall be made only after achievement of the Performance Goals has been certified by the Committee.

 

Section 5.                                                                               General Provisions.

 

5.1                               Compliance with Legal Requirements. This Plan and the granting and payment of Awards, and the other obligations of the Company under this Plan and any Award Agreement or other agreement, shall be subject to all applicable federal and state laws, rules and regulations, and to such approvals by any regulatory or governmental agency as may be required.

 

4

 

5.2                               Authority in Connection with a Change in Control.  Without limiting any provision hereof, in connection with the occurrence of a Change in Control (as defined in the CIC Plan), the Committee shall have the full discretion and authority to waive and/or modify some or all conditions for the payment of Awards hereunder and to provide for such additional or different treatment of Awards hereunder (which shall not be required to be consistent as between different Awards), in each case, as it determines to be necessary or appropriate.  The provisions of this Plan shall not be deemed to amend or modify any provision of the CIC Plan.

 

5.3                               Non-Transferability. Awards shall not be transferable by a Participant except by will or the laws of descent and distribution.

 

5.4                               No Right To Continued Employment. Nothing in this Plan or in any Award granted or any Award Agreement or other agreement entered into pursuant hereto shall confer upon any Participant the right to continue in the employ of the Company or to be entitled to any remuneration or benefits not set forth in this Plan or an Award Agreement (if applicable) or other agreement or to interfere with or limit in any way the right of the Company to terminate such Participant’s employment.

 

5.5                               Withholding Taxes. The Company shall have the right to withhold the amount of any taxes that the Company may be required to withhold before delivery of payment of an Award to the Participant or other person entitled to such payment, or to make such other arrangements for the withholding of taxes that the Company deems satisfactory.

 

5.6                               Amendment, Termination and Duration of this Plan. The Board or the Committee may at any time and from time to time alter, amend, suspend, or terminate this Plan in whole or in part; provided that no amendment that requires shareholder approval in order for this Plan to continue to comply with Code Section 162(m) shall be effective unless the same shall be approved by the requisite vote of the shareholders of the Company. Notwithstanding the foregoing, no amendment shall affect adversely any of the rights of any Participant, without such Participant’s consent, under any Award theretofore granted under this Plan. No Awards may be granted under this Plan after 2020; provided that all payments with respect to Awards previously granted under this Plan shall be paid out pursuant to the terms of this Plan.

 

5.7                               Participant Rights. No Participant shall have any claim to be granted any Award under this Plan, and there is no obligation for uniformity of treatment for Participants. Awards under this Plan shall be subject to any applicable policies of the Company, including without limitation any policies relating to the recoupment of compensation upon a restatement of financial results.

 

5.8                               Unfunded Status of Awards. This Plan is intended to constitute an “unfunded” plan for incentive compensation. With respect to any payments not yet made to a Participant pursuant to an Award, nothing contained in this Plan or any Award shall give any such Participant any rights that are greater than those of a general creditor of the Company.

 

5.9                               Governing Laws. This Plan and all determinations made and actions taken pursuant hereto shall be governed by the laws of the State of New York without giving effect to the conflict of laws principles thereof.

 

5

 

5.10                        Effective Date. This Plan shall take effect upon its adoption by the Board; provided that this Plan shall be subject to the requisite approval of the shareholders of the Company in order to comply with Section 162(m) of the Code. In the absence of such approval, this Plan (and any Awards made pursuant to this Plan with respect to the 2015 fiscal year or thereafter) shall be null and void.

 

5.11                        Beneficiary. A Participant may file with the Committee or its designee a written designation of a beneficiary on such form as may be prescribed by the Committee and may, from time to time, amend or revoke such designation. If no designated beneficiary survives the Participant, the executor or administrator of the Participant’s estate shall be deemed to be the grantee’s beneficiary.

 

5.12                        Interpretation. With respect to an Award granted to a Covered Employee that is intended to qualify as “performance-based compensation” as defined under Section 162(m) of the Code, this Plan shall be administered and construed in accordance with such intention. In addition, Awards made to a Participant under this Plan shall be written, administered and construed in a manner intended to avoid the imposition of the additional tax under Section 409A of the Code.

 

5.13                        Applicability of Company Policy. By accepting an Award under this Plan, each Participant agrees that the terms and conditions of the Company’s Policy Regarding Recoupment or Reduction of Incentive Compensation for Compliance Violations, as in effect from time to time, shall apply to such Participant’s Award(s) under this Plan.

 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]